Newsroom | 48832 results

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red blood cells), in pulmonary and inflammatory bowel disorders (IBD) in the scientific journal Frontiers i...

ANNAPOLIS, Md. & PHILADELPHIA--(BUSINESS WIRE)--Leading breast cancer nonprofits Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) presented new and critical research addressing health disparities, entitled “A New Comprehensive Integrative Care and Navigation Model for Enhancing Outcomes for Black Breast Cancer Patients: Evidence from the Care for HER Program ” at the 2025 San Antonio Breast Cancer Symposium. The Care for HER Program, presented by AstraZeneca, Gilead, and Da...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C.®, a Public Benefit Corporation and parent company of Mandos LLC®, today announced that Mandos received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for adrabetadex, an investigational drug for infantile-onset Niemann-Pick disease type C (NPC). BTD is granted by the FDA to expedite the development of drugs for serious or life-threatening conditions when preliminary clinical evidence may i...

PECHINO, SHANGHAI e HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315), azienda biotech globale impegnata nel progresso della scoperta farmacologica innovativa, oggi ha annunciato la riuscita quotazione allo STAR Market della Borsa di Shanghai. L'operazione fa seguito alla quotazione dell'azienda alla Borsa di Hong Kong, avvenuta nel mese di settembre del 2022, e costituisce una pietra miliare nella trasformazione di Biocytogen ne...

BEIJING & SHANGHAI & HONGKONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. („Biocytogen”, SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das innovative Arzneimittelforschung vorantreibt, gab heute seine erfolgreiche Notierung an der Shanghai Stock Exchange STAR Market bekannt. Dies folgt auf die Notierung des Unternehmens an der Hong Kong Stock Exchange im September 2022 und markiert einen bedeutenden Meilenstein bei der Etablierung von Biocytogen als ers...

PEKÍN, SHANGHÁI Y HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. («Biocytogen», SSE: 688796; HKEX: 02315), empresa biotecnológica global dedicada a la investigación para crear fármacos innovadores, acaba de anunciar su salida a bolsa en el mercado STAR de la Bolsa de Shanghái. Esto se produce tras empezar a cotizar en la Bolsa de Hong Kong en septiembre de 2022 y supone un importante hito para Biocytogen como la primera empresa farmacéutica innovadora global con dobl...

PÉKIN, SHANGHAI et HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (« Biocytogen », SSE : 688796 ; HKEX : 02315), une société internationale de biotechnologie spécialisée dans la découverte de médicaments innovants, a annoncé aujourd’hui son introduction réussie sur le marché STAR de la Bourse de Shanghai. Ce lancement fait suite à celui de la société à la Bourse de Hong Kong en septembre 2022 et marque une étape importante dans l’établissement de Biocytogen en tant q...

BEIJING & SHANGHAI & HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), een wereldwijd biotechnologiebedrijf dat actief is op het gebied van innovatieve geneesmiddelenontwikkeling, heeft vandaag bekendgemaakt dat het met succes is genoteerd aan de STAR Market van de Shanghai Stock Exchange. Dit volgt op de notering van het bedrijf aan de Hong Kong Stock Exchange in september 2022 en markeert een belangrijke mijlpaal in de positio...

BEIJING & SHANGHAI & HONG KONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcin...